Impilo and SHS Capital Acquire Lowenco A/S

KKR and Impilo Acquire Immedica Pharma

January 24, 2025

Pharmaceuticals

KKR and Nordic healthcare investor Impilo have completed a joint acquisition of Stockholm-based Immedica Pharma, with Immedica management reinvesting alongside the new owners. Immedica is a commercial-stage pharmaceutical company focused on rare and specialty diseases (notably hematology, oncology and genetic/metabolic disorders) with ~€100m revenue and more than 120 employees; CVC Credit provided debt financing and Impilo used a single-asset continuation fund supported by secondary investors.

SHS Capital and LPs Invest ~€10M in Develco Pharma

October 7, 2024

Pharmaceuticals

SHS Capital, together with its limited partners and other existing shareholders, is investing approximately €10 million in Develco Pharma to expand manufacturing capacity and accelerate product development in response to exceptionally strong demand. Develco, a specialty pharma developer and manufacturer of modified-release formulations headquartered in Pratteln (DACH region), has been backed by SHS since 2020 and reports an order book exceeding 12 months of revenue.

SHS Invests in Develco Pharma

December 17, 2020

Pharmaceuticals

Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH is making a minority growth investment from its SHS V fund in Swiss-German specialty drug company Develco Pharma. Develco, headquartered in Pratteln, Switzerland with ~125 employees and production in Schopfheim, Germany, develops and manufactures orally administered prolonged-release medicines and will use the investment to broaden its pipeline and expand capabilities.

SHS Capital and ING Corporate Investments Acquire Majority Stake in CAM Bioceramics

July 7, 2023

Medical Devices

German healthcare specialist investor SHS Capital, together with ING Corporate Investments and several co-investors, acquired a majority stake in CAM Bioceramics B.V., a Leiden-based contract development and manufacturing organization (CDMO) for orthobiologic calcium phosphate solutions. Existing owners rolled over a significant stake and management remains in place; the transaction aims to strengthen the business and accelerate investment in people, capabilities and customer partnerships to drive growth.

MidEuropa Acquires Majority Stake in the MBL Group

December 19, 2025

Medical Devices

MidEuropa has acquired a majority stake in the MBL Group, a leading European contract development and manufacturing organisation (CDMO) for assisted mobility, rehabilitation and aged-care equipment. INVL Baltic Sea Growth Fund has fully exited its shareholding while the Lauritsen family has reinvested and CEO Martin Lauritsen will continue to lead the business as MidEuropa supports international growth and capability expansion. MBL employs approximately 1,700 people across Europe and Asia and holds over 100 registered patents.

Impilo Acquires Majority Stake in tandlægen.dk

January 1, 2022

Dental

Impilo, a Nordic healthcare-focused investment company, has acquired a majority stake in tandlægen.dk, Denmark’s leading dental clinic chain. The clinic leaders and management have reinvested part of their proceeds and will partner with Impilo to support further growth, quality improvements and digitalisation across the chain’s 52 clinics and ~800 employees.